X4 Pharma Lands $60M PIPE Financing While Leadership Overhaul Gets Underway

X4 Pharmaceuticals has secured $60 million in private placement equity financing, with the transaction anticipated to close by mid-August. The funding round brings notable leadership changes to the biotech company, as outgoing executives clear the way for fresh management direction.

Leadership Transition in Motion

The company’s former President and CEO Paula Ragan and CFO Adam Mostafa have exited their positions effective immediately. To fill these vacancies, X4 has brought in Adam Craig as Executive Chair, John Volpone as President, and David Kirske as Chief Financial Officer. All three executives previously held positions at CTI BioPharma, bringing deep industry experience to their new roles.

PIPE Deal Terms and Structure

Under the financing agreement, X4 will issue approximately 11.04 million shares priced at $1.42 per share at closing. Alternatively, investors can opt for pre-funded warrants allowing them to purchase up to 31.23 million shares. This flexible structure provides investors with options suited to their investment profiles.

Capital Deployment Strategy

The $60 million raised will primarily fuel commercialization efforts for mavorixafor, X4’s lead therapeutic candidate targeting WHIM syndrome—a rare immunodeficiency disorder characterized by warts, hypogammaglobulinemia, and myelokathexis. Beyond immediate commercialization, the company will continue advancing mavorixafor development for potential regulatory approval in chronic neutropenia, another serious blood disorder indication.

Strong Investor Coalition Behind the Round

This financing demonstrates continued confidence in X4’s pipeline and business plan. Coastlands Capital is leading the round, with existing investors Bain Capital Life Sciences and New Enterprise Associates (NEA) participating. The investor syndicate also includes prominent life sciences funds: BVF Partners LP, Deep Track Capital, Kalehua Capital, Nantahala Capital, Stonepine Capital Management, and Trails Edge Capital Partners. This diverse group of established investors underscores the round’s credibility and signals bullish sentiment toward the company’s therapeutic programs.